Login · Contact

Akorn Pharmaceuticals

Akorn Investor Relations
2018 Press Releases
Keyword Search
2018 | 2017
04/23/18Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement
LAKE FOREST, Ill.--(BUSINESS WIRE)--Apr. 23, 2018-- Akorn, Inc. (NASDAQ:AKRX), today filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement: “Fresenius’ attempt to terminate the transaction on the pretext that the findings from the ongoing investigation are a breach of the merger agreement is completely witho... 
Printer Friendly Version
04/22/18Akorn Issues Statement
LAKE FOREST, Ill.--(BUSINESS WIRE)--Apr. 22, 2018-- Akorn, Inc. (NASDAQ:AKRX), today issued a statement in response to Fresenius Kabi’s announcement that it is seeking to terminate the definitive merger agreement announced on April 24, 2017. “We categorically disagree with Fresenius’ accusations. The previously disclosed ongoing investigation, which is not a condition to closing, has not found any facts that would result in a material adverse eff... 
Printer Friendly Version
02/26/18Akorn Issues Statement on Investigation
LAKE FOREST, Ill., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today issued the following statement: “Akorn and Fresenius Kabi AG, with the assistance of outside consultants, are investigating alleged breaches of FDA data integrity requirements relating to product development at the Company.  To date, the Company’s investigation has not found any facts that would result in a material impact on Akorn’s operations and the Co... 
Printer Friendly Version